Search

Your search keyword '"O’Lone, Raegan"' showing total 5 results
Start Over Author "O’Lone, Raegan" Journal jco precision oncology
5 results on '"O’Lone, Raegan"'

1. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study

Author

Ahn, Eugene R., primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ali-Ahmad, Hussein M., additional, Chan, John, additional, Maitland, Michael L., additional, Patel, Sapna R., additional, Reese, Zachary, additional, Balmanoukian, Ani S., additional, Drescher, Charles W., additional, Li, Rui, additional, Tsimberidou, Apostolia M., additional, Leath, Charles A., additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, Halabi, Susan, additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

2. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study

Author

Yang, Eddy S., primary, Halabi, Susan, additional, Rothe, Michael, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, Pisick, Evan, additional, Dib, Elie, additional, Burgess, Earle F., additional, Zakem, Michael, additional, Rohatgi, Nitin, additional, Bilen, Mehmet A., additional, O'Lone, Raegan, additional, Grantham, Gina N., additional, and Schilsky, Richard L., additional

Published
2023
Full Text
View/download PDF

3. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Klute, Kelsey A., primary, Rothe, Michael, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, Nazemzadeh, Reza, additional, Yost, Kathleen J., additional, Duvivier, Herbert L., additional, Ahn, Eugene R., additional, Cannon, Timothy L., additional, Alese, Olatunji B., additional, Krauss, John C., additional, Thota, Ramya, additional, Calfa, Carmen J., additional, Denlinger, Crystal S., additional, O'Lone, Raegan, additional, Halabi, Susan, additional, Grantham, Gina N., additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

4. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study

Author

Gupta, Ranju, primary, Meric-Bernstam, Funda, additional, Rothe, Michael, additional, Garrett-Mayer, Elizabeth, additional, Mangat, Pam K., additional, D'Andre, Stacy, additional, Ahn, Eugene R., additional, O'Lone, Raegan, additional, Halabi, Susan, additional, Grantham, Gina N., additional, and Schilsky, Richard L., additional

Published
2022
Full Text
View/download PDF

5. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1 / 2 Mutation: Results From the TAPUR Study.

Author

Yang, Eddy S., Halabi, Susan, Rothe, Michael, Garrett-Mayer, Elizabeth, Mangat, Pam K., Pisick, Evan, Dib, Elie, Burgess, Earle F., Zakem, Michael, Rohatgi, Nitin, Bilen, Mehmet A., O'Lone, Raegan, Grantham, Gina N., and Schilsky, Richard L.

Subjects
PROSTATE cancer patients, PROSTATE cancer, BRCA genes, OLAPARIB, CANCER patients, PROGRESSION-free survival
Abstract

PURPOSE: The TAPUR Study is a phase II basket trial that aims to evaluate activity of approved targeted agents in patients with advanced cancers with potentially actionable genomic variants. Data from a cohort of patients with metastatic castrate-resistant prostate cancer (mCRPC) and BRCA1 / 2 mutations treated with olaparib are reported. METHODS: Eligible patients with measurable mCRPC were matched to treatment according to protocol-specified genomic matching rules. Patients had no remaining standard treatment options, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ function. Simon's two-stage design was used with a primary end point of disease control, defined as objective response or stable disease of at least 16-week duration. Secondary end points include radiographic progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Thirty patients with mCRPC with BRCA1 / 2 mutations were treated with olaparib. The disease control rate was 69% (95% CI, 51 to 81), and the objective response rate was 58% (95% CI, 37 to 77). The median radiographic progression-free survival and the median overall survival were 38.4 (95% CI, 16.3 to 52.1) weeks and 76.4 (95% CI, 49.3 to 106.0) weeks, respectively. Six of 30 (20%) patients experienced grade 3-4 adverse or serious adverse events including anemia, aspiration, decreased WBC count, and fatigue. CONCLUSION: Olaparib has antitumor activity in patients with mCRPC with BRCA1 / 2 mutations and warrants further study to determine how to best integrate it into the standard treatment of patients with BRCA1 / 2 -mutated prostate cancer. Olaparib showed a positive signal of activity in real-world patients w/prostate cancer w/BRCA1 or BRCA2 mutations @ASCO #TAPUR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results